Expression of programmed death-ligand 1 (PD-L1) in human pituitary neuroendocrine tumor
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Expression of programmed death-ligand 1 (PD-L1) in human pituitary neuroendocrine tumor
Authors
Keywords
-
Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-05-23
DOI
10.1007/s00262-020-02611-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Analysis of Tumor Angiogenesis and Immune Microenvironment in Non-Functional Pituitary Endocrine Tumors
- (2019) Mizuto Sato et al. Journal of Clinical Medicine
- Targeting PD-L1 initiates effective anti-tumor immunity in a murine model of Cushing's Disease
- (2019) Hanna R Kemeny et al. CLINICAL CANCER RESEARCH
- The Epigenomic Landscape of Pituitary Adenomas Reveals Specific Alterations and Differentiates Among Acromegaly, Cushing's Disease and Endocrine-Inactive Subtypes
- (2018) Matthew P. Salomon et al. CLINICAL CANCER RESEARCH
- The expression profile of PD-L1 and CD8+ lymphocyte in pituitary adenomas indicating for immunotherapy
- (2018) Peng-fei Wang et al. JOURNAL OF NEURO-ONCOLOGY
- Increase in PD-L1 expression after pre-operative radiotherapy for soft tissue sarcoma
- (2018) Kirtesh R. Patel et al. OncoImmunology
- Marked response of a hypermutated adrenocorticotropic hormone-secreting pituitary carcinoma to ipilimumab and nivolumab
- (2018) Andrew L Lin et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011–2015
- (2018) Quinn T Ostrom et al. NEURO-ONCOLOGY
- European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas
- (2017) Gerald Raverot et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer
- (2017) Andreas H Scheel et al. HISTOPATHOLOGY
- Diagnosis and Treatment of Pituitary Adenomas
- (2017) Mark E. Molitch JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Outcome of Nonfunctioning Pituitary Adenomas That Regrow After Primary Treatment: A Study From Two Large UK Centers
- (2017) Metaxia Tampourlou et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Risk of Recurrence in Pituitary Neuroendocrine Tumors: A Prospective Study Using a Five-Tiered Classification
- (2017) Gérald Raverot et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non–Small-Cell Lung Cancer
- (2017) Reinhard Büttner et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy
- (2016) Thomas K. Eigentler et al. CANCER TREATMENT REVIEWS
- Clinical Impact of the Current WHO Classification of Pituitary Adenomas
- (2016) W. Saeger et al. ENDOCRINE PATHOLOGY
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors
- (2016) Yu Mei et al. Oncotarget
- Classifying Cancers Based on T-cell Infiltration and PD-L1
- (2015) Michele W.L. Teng et al. CANCER RESEARCH
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights
- (2015) Alexander Faje Pituitary
- ENDOCRINE SIDE-EFFECTS OF ANTI-CANCER DRUGS: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses
- (2013) Francesco Torino et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas
- (2008) Roger Gejman et al. HUMAN PATHOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started